Switch View
© Globe Newswire
06.10.2025
ISIN: US6294441000
NRx Pharmaceuticals, Inc.
NRXP
LISTED
NASDAQ
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
News Preview
WILMINGTON, Del., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, will present at the Noble Capital Mar...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US03969K1088
Arcutis Biotherapeutics Inc
ARQT
LISTED
NASDAQ
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
News Preview
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US58468P2065
MediciNova Inc
MNOV
LISTED
NASDAQ
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
News Preview
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
06.10.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness Signs 1st Ottawa, Ontario Real-Estate Location with Multi-Unit & Multi-Branded Franchisee
News Preview
Toronto, Ontario--(Newsfile Corp. - October 6, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across Canada is pleased to announce that an existing multi-unit franchisee of Via Cibo has successfully secured a real estate location for Heal Wellne...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
06.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Nutex Health and its Hospitals Earn Record-Breaking 20 Awards and Accolades in Q3
News Preview
HOUSTON, Oct. 6, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physicia...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US21077P1084
Context Therapeutics Inc.
CNTX
LISTED
NASDAQ
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
News Preview
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced two posters will be presented at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Me...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US57055L1070
Marker Therapeutics, Inc.
MRKR
LISTED
NASDAQ
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
News Preview
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US00534A1025
Invivyd Inc
IVVD
LISTED
NASDAQ
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
News Preview
NEW HAVEN, Conn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application and provided feedback to advance the company’s REVOLUTION clinical program, Invivyd’s development program for VYD2311, a vaccine alte...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.10.2025
ISIN: DE000A40AEG0
Pentixapharm Holding AG
PTP
LISTED
XETR
Pentixapharm präsentiert erweiterte CXCR4-Radiopharmazeutika-Plattform mit neuen klinischen Ergebnissen auf EANM 2025 Kongress
News Preview
Pentixapharm präsentiert erweiterte CXCR4-Radiopharmazeutika-Plattform mit neuen klinischen Ergebnissen auf EANM 2025 Kongress
Klinische Daten aus unabhängigen prüferinitiierten Studien mit [⁶⁸Ga]Ga-PentixaFor zeigen Potenzial zur verbesserten Diagnostik des Primären Hyperaldosteronismus (PA)
Erste klinische Ergebnisse mit [¹⁷⁷Lu]Lu-PentixaTh......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.10.2025
ISIN: DE000A40AEG0
Pentixapharm Holding AG
PTP
LISTED
XETR
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
News Preview
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism
First-in-human findings with [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer show early......
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US4158581094
Harrow Inc
HROW
LISTED
NASDAQ
ImprimisRx Announces Leadership Changes
News Preview
Frank Mullery Appointed Chief Executive Officer of ImprimisRx...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US68232V8019
Traws Pharma Inc.
TRAW
LISTED
NASDAQ
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
News Preview
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of director...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
06.10.2025
ISIN: US15117F3029
Cellectar Biosciences, Inc.
CLRB
LISTED
NASDAQ
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
News Preview
Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in Early 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US55234L1052
Lyra Therapeutics, Inc.
LYRA
LISTED
NASDAQ
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
News Preview
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission ...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US87583X1090
Tango Therapeutics Inc
TNGX
LISTED
NASDAQ
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
News Preview
Company to present three posters at SITC Annual Meeting 2025 Company to present three posters at SITC Annual Meeting 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US5787841007
Maze Therapeutics Inc
MAZE
LISTED
NASDAQ
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
News Preview
Maze Therapeutics appoints industry veteran Hervé Hoppenot as Chairman of the Board of Directors...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 6, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDA...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
Medical Care Technologies (OTC PINK:MDCE) Launches Next-Generation AI Validation Program Targeting Clinical-Grade Accuracy
News Preview
MESA, AZ / ACCESS Newswire / October 6, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) announced its plan to benchmark its upcoming AI diagnostic model against the HAM10000 public dermatology dataset to validate its image recognition architecture for detecting various skin lesion types. The benchmarking process will help evaluate model prec...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: US29350E1047
Enochian Biosciences, Inc
ENOB
LISTED
NASDAQ
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline
News Preview
LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 6, 2025 / Lunai Bioworks (Nasdaq:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and metabolic data. The company is launching a preclinical Alzheimer's progra...
Themefolio
Profiler
Peergroup
© Newsfile
06.10.2025
ISIN: CA24463V1013
Defence Therapeutics Inc.
DTC
LISTED
CSE
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
News Preview
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 20...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: US47010C4096
Jaguar Health, Inc.
JAGX
LISTED
NASDAQ
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
News Preview
Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) of approximately 37% SAN FRANCISCO, CA, AL / ACCESS Newswire / October 6, 2025 / Jaguar Health, Inc. (N...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
News Preview
LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
News Preview
LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: US60785L2079
Modular Medical, Inc.
MODD
LISTED
NASDAQ
Modular Medical Appoints David Bosshard to Lead its International Expansion for the Pivot Insulin Delivery System
News Preview
-Seasoned Executive with Proven Track Record in International Pump Launches to Accelerate Global Adoption of User Friendly, Affordable Patch Pumps SAN DIEGO, CA, CA / ACCESS Newswire / October 6, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology ta...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: US7389201077
Aspire Biopharma Holdings, Inc
ASBP
LISTED
NASDAQ
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
News Preview
ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery t...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
News Preview
Positive topline results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator’s choice of chemotherapy as first-line treatme...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
ISIN: US8292141053
Simulations Plus Inc
SLP
LISTED
NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
News Preview
NEW YORK, Oct. 6, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: DE000A40AEG0
Pentixapharm Holding AG
PTP
LISTED
XETR
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
News Preview
Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary AldosteronismFirst-in-human findings with [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer show early therapeutic activity, further validating CXCR4 as a clinically relevant target BERLIN, DE / ACCESS Newswire /...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: BE0003874915
Fagron NV
FAGR
LISTED
EURONEXT
Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions
News Preview
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 October 2025 – 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: BE0974358906
Nyxoah S.A.
NYXH
LISTED
NASDAQ
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System
News Preview
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel
News Preview
Basel, 6 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), in collaboration with KlinRisk, Inc., has received the CE-mark for the first AI-based risk stratification tool to assess progressive decline in kidney function. This milestone allows Roche to introduce the Chronic Kidney Disease (CKD) algorithm panel on its navify® Algorithm Suite to suppo...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: GB00BYX3WZ24
Hemogenyx Pharmaceuticals plc
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Clearance to Initiate Pediatric Enrolment
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.MD A...
Themefolio
Profiler
Peergroup
© PR Newswire
05.10.2025
ISIN: US8342033094
Soleno Therapeutics Inc
SLNO
LISTED
NASDAQ
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
News Preview
NEW YORK, Oct. 5, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.10.2025
ISIN: US04335A1051
Arvinas, Inc.
ARVN
LISTED
NASDAQ
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
News Preview
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease –...
Themefolio
Profiler
Peergroup
© PR Newswire
05.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Equity Alert: Kessler Topaz Meltzer & Check, LLP Alerts Shareholders of Securities Fraud Class Action Lawsuit Filed against Lantheus Holdings, Inc. (LNTH)
News Preview
RADNOR, Pa., Oct. 5, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus secur...
Themefolio
Profiler
Peergroup
© PR Newswire
05.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
CLASS ACTION REMINDER: Berger Montague Advises LifeMD, Inc. (NASDAQ: LFMD) Investors to Inquire About a Securities Fraud Lawsuit by October 27, 2025
News Preview
PHILADELPHIA, Oct. 5, 2025 /PRNewswire/ -- Berger Montague PC, national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Cl...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.10.2025
ISIN: US00773J2024
Spyre Therapeutics Inc
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
News Preview
WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced scienti...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ:...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Do you own shares of MOH? Robbins LLP Informs Investors of the Molina Healthcare, Inc. Class Action Lawsuit
News Preview
SAN DIEGO, Oct. 3, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Molina Healthcare, Inc. (NYSE: MOH) securities between February 5, 2025 and July 23, 2025. Molina provides healthcare services to low-income...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK
News Preview
NEW ORLEANS, Oct. 3, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have untilNovember 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquir...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2025
ISIN: US90466Y1038
Unicycive Therapeutics, Inc.
UNCY
LISTED
NASDAQ
UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 3, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the "Class Period"), of the important October 14, 2025 lead plaintiff deadl...
Themefolio
Profiler
Peergroup
© BusinessWire
04.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Molina Healthcare, Inc. Shareholders
News Preview
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Central District of California, captioned Hindlemann v. Molina Healthcare, Inc., et al., Case No. 2:25-cv-09461, on behalf of persons and entities that purchased or otherwise acquired Molina Healthcare, Inc. (“Mol...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Deadline: SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Oct. 3, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDA...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
News Preview
NEW YORK, Oct. 3, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTX Deadline: NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 3, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nutex Health Inc. (NASDAQ: NUT...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2025
ISIN: US98422E1038
Xeris Biopharma Holdings Inc
XERS
LISTED
NASDAQ
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2025, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggreg...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2025
ISIN: US64135M1053
Neurogene Inc
NGNE
LISTED
NASDAQ
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 9,390 shares of t...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2025
ISIN: US34962G1094
Forte Biosciences, Inc.
FBRX
LISTED
NASDAQ
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
News Preview
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.
In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Fort...
Themefolio
Profiler
Peergroup
© Newsfile
03.10.2025
ISIN: CA88410L1022
Thiogenesis Therapeutics, Corp.
TTI
LISTED
TSX
Thiogenesis Announces Extension to Investor Relations Agreement
News Preview
San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds to treat unmet pediatric diseases, announces th...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
BENSALEM, Pa., Oct. 3, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK)....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: BE0974358906
Nyxoah S.A.
NYXH
LISTED
NASDAQ
Publication relating to transparency notifications
News Preview
REGULATED INFORMATION...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US90400D1081
Ultragenyx Pharmaceutical Inc
RARE
LISTED
NASDAQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 62,232 shares of common stock of the...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US21077P1084
Context Therapeutics Inc.
CNTX
LISTED
NASDAQ
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase 30,000 shares of its common stock...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US8776191061
Taysha Gene Therapies Inc
TSHA
LISTED
NASDAQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2025, the Compensation Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US00773J2024
Spyre Therapeutics Inc
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-med...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US28531P1030
electroCore, Inc.
ECOR
LISTED
NASDAQ
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
News Preview
ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Com...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US45826J1051
Intellia Therapeutics Inc
NTLA
LISTED
NASDAQ
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 11 new employees in restrict...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US87164F1057
Syndax Pharmaceuticals Inc
SNDX
LISTED
NASDAQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common stock to 10 new employees under the Company's 2023 Inducemen...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US9290331084
Vor Biopharma Inc.
VOR
LISTED
NASDAQ
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 19, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 76,360 shares of Vor Bio’s common s...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
